What is Ocrelizumab?

Category: Prescription Drugs

Most popular types: Ocrevus

false

Ocrelizumab is a type of monoclonal antibody that works by targeting certain types of cells in the immune system that are believed to contribute to the auto-immune destruction of nerve cells seen in multiple sclerosis.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Multiple sclerosis 143 89
Participate in clinical trial 16 21
MS hug (tight chest or torso) 3 7
Lhermitte's sign 1 0
Slow speech (bradyarthria) 1 0

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 7
Mild 32
None 55

Commonly reported side effects and conditions associated with Ocrelizumab

Side effect Patients Percentage
Fatigue 5
Headaches 5
Nausea 5
Tiredness 3
Weakened immune system 3
Decreased appetite 2

Show all 49 reported side effects

Dosages

Based on patients currently taking Ocrelizumab

Dosage Patients Percentage
30 mg every 6 months 28
600 mg every 6 months 22
1 other every 6 months 5
60 mg every 6 months 5
300 mg every other week 4
15 mg one time 2
300 mg one time 2
300 mg every 6 months 2
30 mg yearly 1
30 mg every 3 months 1

See all 22 dosages

Why patients stopped taking Ocrelizumab

Multiple reasons could be selected

Reason Patients Percentage
Did not seem to work 7
Doctor's advice 1
Expense 1
Other 1
Personal research 1
Side effects too severe 1
See all 9 patients who've stopped taking Ocrelizumab

Duration

Currently taking Ocrelizumab

Duration Patients Percentage
1 - 6 months 10
6 months - 1 year 12
1 - 2 years 31
2 - 5 years 38
5 - 10 years 1

Stopped taking Ocrelizumab

Duration Patients Percentage
Less than 1 month 1
1 - 6 months 1
6 months - 1 year 3
1 - 2 years 6
2 - 5 years 1
Adherence
Adherence Evaluations Percentage
Always 92
Usually 0
Sometimes 0
Never taken as prescribed 2
Burden
Burden Evaluations Percentage
Very hard to take 2
Somewhat hard to take 12
A little hard to take 29
Not at all hard to take 51
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 1
< $25 48
Not specified 45

What people switch to and from

Patients started taking Ocrelizumab after stopping:

Treatment Patients Percentage
Natalizumab (Tysabri) 27
Dimethyl fumarate (Tecfidera) 21
Glatiramer acetate (Copaxone) 18
Fingolimod (Gilenya) 15
Teriflunomide (Aubagio) 14

Show all 16 treatments patients report switching from

Patients stopped taking Ocrelizumab and switched to:

Treatment Patients Percentage
Rituximab (Rituxan) 2
Cladribine (Mavenclad) 1
Fingolimod (Gilenya) 1
Glatiramer acetate (Copaxone) 1
Natalizumab (Tysabri) 1
Last updated:

2 patient evaluations for Ocrelizumab

Apr 20, 2018 (Started )

  • Effectiveness
    Major (for multiple sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Somewhat hard to take
Advice & Tips: Gave me many more days to enjoy as did not have to commute monthly to Philadelphia for Tysabri infusions. Plus I feel wonderful.

  • 0 helpful marks

Sep 29, 2017 (Started Sep 25, 2017)

  • Effectiveness
    Slight (for multiple sclerosis)
  • Side effects
    Mild (nausea)
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 30 mg Every 6 months
Advice & Tips: worth any side effects for improved health. Better dead than not take ocrevus

  • 1 helpful mark
Last updated:
Showing 2 of 2 patient evaluations for Ocrelizumab